The present invention relates to treatment of coronavirus-induced disease, specifically COVID-19 disease, wherein the disease is characterized by mast cell degranulation, acute inflammation, pulmonary and/or vascular pathologies. The treatment comprises administering to a subject a composition comprising a mast cell stabilizer and/or inhibitor of mast cell products, such as TY-51469, nafamostat mesylate, cromolyn, or ketotifen. The invention also provides a method of diagnosing a subject as having SARS-CoV-2, the method comprising determining the level and/or activity of a mast cell protease such as chymase or tryptase in the serum from a subject.

Methods for treatment and diagnosis of pervasive developmental disorders in humans are described.

The present application provides a method of assaying pyruvate dehydrogenase complex (PDHC) activity in a mammalian cell that expresses human sirtuin 4 (SIRT4) comprising measuring a level of a dihydrolipoyllysine acetyltransferase (DLAT) lipoamide peptide comprising the amino acid sequence TDK[lipoyl]AT in the cell. The present application also demonstrates that sirtuin 4 (SIRT4) acts as a cellular lipoamidase that negatively regulates pyruvate dehydrogenase complex (PDHC) activity through hydrolysis of its lipoamide cofactors.

Disclosed are compositions and method related to variants of SPINK2 that bind to targets other than an endogenous target of SPINK2. In one embodiment, a peptide is provided that comprises the amino acid sequence SEQ ID NO: 1. In further embodiments, an amino acid sequences encoded by nucleotide positions 4 to 42 and/or nucleotide positions 94 to 189 in the nucleotide sequence of SEQ ID NO: 14 flank the amino terminus and the carboxyl terminus, respectively, of the amino acid sequence. In another embodiment, a peptide is provided that comprises an amino acid sequence derived from the amino acid sequence of SEQ ID NO: 1 in which a conservative substitution, deletion, addition and/or insertion of 1 to 5 (inclusive) amino acids has occurred at amino acids other than the 1st Xaa to the 12th Xaa counting from the amino terminus.

A method of measuring and identifying LSD and its major metabolite O-H-LSD, by obtaining a sample from an individual, and measuring, identifying, and quantifying LSD and O-H-LSD in the sample by performing a LC-MS/MS analysis. A method of treating and monitoring individuals taking LSD, by administering a microdose of LSD, a prodrug of LSD, or an analog of LSD to the individual, monitoring the individual by obtaining a sample from an individual and measuring and identifying the analytes in the sample by performing a LC-MS/MS analysis, and adjusting the microdose based on the amount of LSD quantified in the LC-MS/MS analysis. A method of adjusting dosing of LSD, by administering a microdose of LSD, a prodrug of LSD, or an analog of LSD to the individual, and adjusting the microdose based on blood concentration analytics.

Provided are methods for the detection of GDF11 in a subject having or suspected of having a mood and/or anxiety disorder, comprising providing a sample from a subject having or suspected of having a mood and/or anxiety disorder; contacting the sample with a GDF11-binding molecule; and detecting bound GDF11. Also provided are methods of diagnosing or characterizing a mood and/or anxiety disorder in a subject, comprising providing a sample from a subject; contacting the sample with a GDF11-binding molecule; detecting bound GDF11; and comparing the levels of detected bound GDF11 to healthy reference levels. Also provided are methods of treating or preventing a mood and/or anxiety disorder and/or accelerated aging in a subject in need thereof, comprising administering to the subject an agent or composition which increases the levels of GDF11 polypeptide in the subject.

The present disclosure relates to methods for characterizing and diagnosing dental diseases. In particular, the present disclosure relates to methods for characterizing and diagnosing dental disease (e.g., gingivitis and periodontal disease) based on levels of AI-2 in oral fluids and plaque.

The present disclosure provides a library of engineered DNASE proteins (including DNASE1, DNASE1-LIKE 1, DNASE1-LIKE 2, DNASE1-LIKE 3, DNASE2A, DNASE2B) that allows to select drug candidates for developing therapeutics for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the selected DNase variant has improved properties, including properties amenable to clinical development, including manufacturing, toxicology, pharmacokinetic, and/or use in therapy.

A method of identifying an effective composition of antigens for a tumor vaccine includes determination of antibodies produced by at least 10 patients after vaccination with an autologous vaccine obtained by gathering tumor material from the patients, separating the tumor cells from accompanying tissue, inactivating the tumor cells and providing them in a form suitable for administration as autologous vaccine, application of the autologous vaccine to the patients, isolation and determination of the antibodies produced by the patients' immune response that have been found to be shared by at least 80% of the patients, and identifying the antigens corresponding to the determined antibodies. A method of manufacturing a tumor vaccine is performed from the identified antigens and danger signals, and a tumor vaccine is obtained thereby.

Disclosed herein are methods for evaluation, selection, optimization, and design of Cas9 molecule/gRNA molecule complexes.